Association between hyperuricemia, hypertension, dyslipidemia and cardiovascular events in a large East Siberian region

Aim. To assess the association between hyperuricemia (HU), as well as its combination with hypertension (HTN), dyslipidemia and car­dio­vascular events.

Material and methods. This retrospective analysis included a re­presentative sample of 1603 residents of Krasnoyarsk Krai aged 25-64 years from the Russian epidemiological study ESSE RF. Uric acid >360 μmol/l was taken as the HU criterion. Statistical processing included logistic regression with sequential exclusion of insignificant factors to search for associations between HU, HTN and lipid metabolism disorders with cardiovascular events — stroke, myocardial infarction (MI) and coronary artery disease (CAD).

Results. The prevalence of HU was 34,6%, among men — 47,6%, among women — 26,1%. No significant differences in the frequency of MI, stroke and CAD among individuals with and without HU were found. Regression model revealed a significant increase in the risk of stroke (odds ratio (OR) 5,7; 95% confidence interval (CI): 1,68-19,34) and CAD (OR 4,99; 95% CI: 2,73-9,09), but not MI, as well as stroke (OR 2,95; 95% CI: 1,31-6,64) (p=0,009), but not MI and CAD, when HU was combined with HTN.

Conclusion. No significant association was found between HU and cardiovascular events. However, the combination of HU with HTN, as well as HU with low high-density lipoprotein cholesterol, was significantly associated with stroke and CAD.

1. Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5-22. (In Russ.) doi:10.38109/2075-082X-2022-1-5-22.

2. Shalnova SA, Deyev AD, Artamonova GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153-9. (In Russ.) doi:10.20996/1819-6446-2014-10-2-153-159.

3. Butler F, Alghubayshi A, Roman Y. The Epidemiology and Genetics of Hyperuricemia and Gout across Major Racial Groups: A Literature Review and Population Genetics Secondary Database Analysis. J Pers Med. 2021;11(3):231. doi:10.3390/jpm11030231.

4. Kobalava ZhD, Troitskaya EA. Asymptomatic Hyperuricemia and Risk Of Cardiovascular and Renal Diseases. Kardiologiia. 2020;60(10):113-21. (In Russ.) doi:10.18087/cardio.2020.10.n1153.

5. Jiang H, Su Y, Liu R, et al. Hyperuricemia and the risk of stroke incidence and mortality: A systematic review and meta-analysis. Arch Rheumatol. 2025;40(1):128-43. doi:10.46497/ArchRheumatol.2025.10808.

6. Goncalves DLN, Moreira TR, da Silva LS. A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep. 2022;12(1):6251. doi:10.1038/s41598-022-10118-x.

7. Mazurov VI, Drapkina OM, Martynov АI, et al. Meta-analysis of observational cohort studies on the relationships of asymptomatic hyperuricemia with chronic kidney disease. Therapy. 2023; 9(10):21-39. (In Russ.) doi:10.18565/therapy.2023.10.21-39.

8. Rabbani MG, Alif SM, Tran C, et al. Higher serum uric acid levels and risk of allcause mortality in general population: a systematic review and meta-analysis. Metabol Open. 2025;26:100371. doi:10.1016/j.metop.2025.100371.

9. Vareldzis R, Perez A, Reisin E. Hyperuricemia: An Intriguing Connection to Metabolic Syndrome, Diabetes, Kidney Disease, and Hypertension. Curr Hypertens Rep. 2024;26(6):237-45. doi:10.1007/s11906-024-01295-3.

10. Raya-Cano E, Vaquero-Abellán M, Molina-Luque R, et al. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18412. doi:10.1038/s41598-022-22025-2.

11. Wang B, Ma C, Wu J, et al. Association between novel adiposity parameters and hyperuricemia: a cross-sectional study. Front Nutr. 2025;12:1536893. doi:10.3389/fnut.2025.1536893.

12. Grinshtein YuI, Shabalin VV, Ruf RR, et al. The prevalence of metabolic syndrome in the Krasnoyarsk Krai population and the features of its association with hyperuricemia. Russian Journal of Cardiology. 2020;25(6):3852. (In Russ.) doi:10.15829/1560-4071-2020-3852.

13. Mironova OYu. Hyperuricemia: contemporary treatment in patients with cardiovascular disease. Eurasian Heart J. 2022;(2):72-8. (In Russ.) doi:10.38109/2225-1685-2022-2-72-78.

14. Koziolova NA, Chernyavina AI. Hypertension and asymptomatic hyperuricemia: algorithm of diagnostics and management (literature review). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2022;28(4):316-27. (In Russ.) doi:10.18705/1607-419X-2022-28-4-316-327.

15. Mazurov VI, Sayganov SА, Martynov AI, et al. Impact of uratelowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials. Herald of North-Western State Medical University named after I. I. Mechnikov. 2023;15(4):5-18. (In Russ.) doi:10.17816/mechnikov604850.

16. Drapkina OM, Mazurov VI, Martynov AI, et al. "Focus on hyper­uri­cemia". The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023;22(4):3564. (In Russ.) doi:10.15829/1728-8800-2023-3564.

17. Chazova IE, Chikhladze NM, Blinova NV, et al. Clinical guidelines of the Russian Federation Medical Society on Arterial Hypertension (RSH) and the Eurasian Association of Cardiologists (EAC) for the diagnosis and treatment of arterial hypertension (2024). Systemic Hypertension. 2024;21(4):5-109. (In Russ.) doi:10.38109/2075-082X-2024-4-5-109.

18. Sumpter NA, Saag KG, Reynolds RJ, et al. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol. 2020;32(2):126-33. doi:10.1097/BOR.0000000000000691.

19. Johnson RJ, Sanchez Lozada LG, et al. Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney Int Rep. 2022;8(2):229-39. doi:10.1016/j.ekir.2022.11.016.

20. Boytsov SA, Chazov EI, Shlyakhto EV, et al. Scientific and Organizing Committee of the Russian Federation essay. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. The Russian Journal of Preventive Medicine. 2013;16(6):25-34. (In Russ.)

21. Zheng L, Zhu Y, Ma Y, et al. Relationship between hyperuricemia and the risk of cardiovascular events and chronic kidney disease in both the general population and hypertensive patients: A systematic review and meta-analysis. Int J Cardiol. 2024;399:131779. doi:10.1016/j.ijcard.2024.131779.

22. Li L, Song Q, Yang X. Lack of Associations between Elevated Se­rum Uric Acid and Components of Metabolic Syndrome Such as Hypertension, Dyslipidemia, and T2DM in Overweight and Obese Chinese Adults. J Diabetes Res. 2019;2019:3175418. doi:10.1155/2019/3175418.

23. Shalnova SA, Imaeva AE, Kutsenko VA, et al. Hyperuricemia and hypertension in workingage people: results of a population study. Cardiovascular Therapy and Prevention. 2023;22(9S):3783. (In Russ.) doi:10.15829/1728-8800-2023-3783.

24. Li X, Meng X, He Y, et al. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: a phenomewide mendelian randomization study. PLoS Med. 2019;16(10):e1002937. doi:10.1371/journal.pmed.1002937.

25. Jordan DM, Choi HK, Verbanck M, et al. No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Med. 2019;16(1):e1002725.

26. Plotnikov DY. Mendelian randomization: using genetic information in epidemiological studies (review). Research Results in Biomedicine. 2023;9(2):158-72. (In Russ.) doi:10.18413/2658-6533-2023-9-2-0-1.

27. Shabalin VV, Grinshtein YuI, Ruf RR, et al. Asymptomatic hyper­uri­cemia: obvious, controversial, hypothetical. The Russian Journal of Preventive Medicine. 2023;26(7):103-9. (In Russ.) doi:10.17116/profmed202326071103.

28. Shabalin VV, Samsonov NS, Grinshtein YuI. Asymptomatic Hyperuricemia as a Cardiovascular Risk Factor: to Treat or Not to Treat? Lechebnoe delo. 2023;3:132-40. (In Russ.) doi:10.24412/2071-5315-2023-12994.

29. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178.

30. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi:10.15829/1560-4071-2024-6117.